CNS seniors ride again as Merck KGaA strikes new Newron deal
This article was originally published in Scrip
Newron Pharmaceuticals has received a development licence for two compounds, broadening the scope of its collaboration with Merck Serono (Merck KGaA). The two companies are already collaborating on the development of safinamide in Parkinson's disease.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.